Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
|
|
- Irene Parker
- 7 years ago
- Views:
Transcription
1 Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Leeds RGC Approved: Sept Disorder/condition approved name and symbol as published on the OMIM Malignant Hyperthermia, susceptibility to, 1 (MHS1) Malignant Hyperthermia, susceptibility to, 5 (MHS5) database (alternative names will be listed on the (Note, malignant hyperthermia is also known as UKGTN website) malignant hyperpyrexia) 2. OMIM number for disorder/condition , a. Disorder/condition please provide, in laymen s terms, a brief (2-5 sentences) description of how the disorder(s) affect individuals and prognosis. 3b Disorder/condition if required please expand on the description of the disorder provided in answer to Q3a. MH susceptibility predisposes to a potentially fatal reaction to the most commonly used anaesthetic drugs. Susceptible individuals are usually healthy but exposure to the triggering drugs causes a loss of calcium regulation in skeletal muscle cells leading to muscle spasm, a profound increase in metabolic activity and muscle cell disruption. Survival depends on prompt recognition of the evolving reaction and appropriate treatment by the anaesthetist. If a patient is known to be at increased risk for MH, a reaction can be avoided by the use of alternative anaesthetic drugs that are known not to trigger the condition. While most patients susceptible to MH are apparently healthy unless exposed to the triggering anaesthetics, there are some MH susceptible individuals who present in other ways. Known associations with MH susceptibility are exertional rhabdomyolysis, hyperckaemia and exertional heat illness. Patients with congenital myopathies with a RYR1 aetiology (central core disease, multiminicore myopathy) are also at risk of developing malignant hyperthermia if their RYR1 mutation results in gain of function of the RyR1 channel. Loss of function RYR1 mutations are not associated with MH susceptibility. There are also rare reports of MH susceptible children with nonspecific clinical and histological myopathic features who present with apparently spontaneous episodes of fever and muscle rigidity that can prove fatal. Finally late onset myopathy has also recently been described as a presenting feature of MH susceptibility. 4. Disorder/condition mode of inheritance MH susceptibility was originally described as an autosomal dominant condition with incomplete penetrance. There is mounting evidence that MH susceptibility is one of a growing number of presumed single gene disorders that deviates from a simple Mendelian model of inheritance. Indeed, inheritance of MH can be best explained by a threshold model: approximately 8% of UK MH families appear to have more than one genetic factor making a major contribution to the risk of MH susceptibility.
2 5. Gene approved name(s) and symbol as published on HGNC database (alternative names will be listed on the UKGTN website) ryanodine receptor 1 (skeletal); RYR1 calcium channel, voltage-dependent, L type, alpha 1S subunit; CACNA1S 6a. OMIM number for gene(s) , b HGNC number for gene(s) 10483, a. Gene description(s) RYR1, chromosomal location 19q13.1, encodes the skeletal muscle ryanodine receptor isoform. This protein forms the monomeric subunits of the tetrameric calcium release channel of skeletal muscle sarcoplasmic reticulum. The gene encompasses 158 Kb gdna and contains 106 exons with the cdna (~15 Kb) encoding a protein monomer of 5038 amino acids with a mass of 563,584 Da. CACNA1S, chromosomal location 1q32, encodes the pore-forming subunit of the pentameric calcium channel/voltage sensor of the skeletal muscle sarcoplasmic membrane. The gene encompasses 73 Kb gdna and contains 44 exons with the cdna (~ 5.6 Kb) encoding a protein of 1873 amino acids with a mass of 212,350 Da. 7b. Number of amplicons to provide this test (molecular) or type of test (cytogenetic) 7c. GenU band that this test is assigned to for index case testing 8. Mutational spectrum for which you test including details of known common mutations 32 long PCR fragments (23 for RYR1 and 9 for CACNA1S) to include all exons and intronic boundaries. G ( amplicons) Analysis of entire coding region and splice junctions for all potentially deleterious variants (which we define as missense, nonsense, indels, or in a putative splice site) in RYR1 and CACNA1S. Of these, 30 RYR1 ( and 2 CACNA1S (Monnier et al. Am J Hum Genet 1997; 60: ; Weiss RG et al Am J Physiol Cell Physiol 2004; 287: C ; Carpenter D et al BMC Med Genet 2009; 10:104; Eltit JM et al Proc Nat Acad Sci 2012; 109: ) have been functionally characterised and meet international consensus criteria for diagnostic use in MH. 9a. Technical method(s) Panel test using NGS involving clonal sequencing of indexed multiplexed samples. PCR amplification of coding and flanking (minimum 20bp) intronic sequence. NGS analysis using Illumina (HiSeq or MiSeq) platform. 9b If a panel test using NGS please state if it is a conventional panel or a targeted exome test. 9c. Panel/targeted exome Tests i) Do the genes have 100% coverage? If not what is the strategy for dealing with the gaps in coverage? Gene-centric approach for RYR1 and CACNA1S We have sequenced RYR1 and CACNA1S in 48 samples. For RYR1 there is 96-99% coverage, with % coverage of CACNA1S. There is an average read depth of 200. Missing fragments are sequenced using Sanger sequencing.
3 ii) Does the test include MLPA? iii) Does this use sanger sequencing or Next Generation Sequencing (NGS)? iv) If NGS is used, does the lab adhere to the Practice Guidelines for NGS? 10 Is the assay to be provided by the lab or is it to be outsourced to another provider? If to be outsourced, please provide the name of the laboratory. 11. Validation process Please explain how this test has been validated for use in your laboratory or submit your internal validation documentation No NGS Yes Provided by the lab 12a. Are you providing this test already? No x Yes 12b. If yes, how many reports have you produced? Please provide the time period in which these reports have been produced and whether in a research or a full clinical diagnostic setting. Next generation sequencing workflow has been validated and applied to provision of our BRCA and HNPCC cancer services. The approach was been validated in a pilot study of 55 cases (Morgan et al., 2010 Human Mutation 31: ). An additional study of 50 cases analysed in parallel with Sanger sequencing was fully concordant for 485 variants (100% sensitivity). See details below of statistical analysis (section on analytical sensitivity and specificity). All long range primers were checked for SNPs. A minimum sequence coverage threshold was set at depth of 50 sequence reads. Diagnostic Next Generation sequencing pathways for BRCA and HNPCC genes have been established in service for 2.5 years and 1.5 years respectively. This workflow was also audited by the peer assessors during our most recent laboratory CPA assessment (May 2010). Have provided a diagnostic service for functionally characterised RYR1 mutations ( in a full clinical diagnostic setting since 2003 (1020 samples tested). In a research setting we have carried out Sanger sequencing of cdna extracted from skeletal muscle of RYR1 (192 samples) and CACNA1S (50 samples) since 2004 and 2007 respectively. We commenced NGS sequencing of RYR1 and CACNA1S in a research setting in April 2012 (48 samples) 12c. Number of reports mutation positive 470 (468/1260 RYR1, 2/98 CACNA1S) 12d. Number of reports mutation negative For how long have you been providing See 12b above this service? 14a. Is there specialised local clinical/research expertise for this disorder? No x Yes 14b. If yes, please provide details The Leeds MH Investigation Unit has been the national referral centre since With more than
4 15. Are you testing for other genes/disorders/conditions closely allied to this one? Please give details 6000 patients tested by muscle biopsy and/or DNA analysis, the Leeds unit has the greatest experience of MH diagnosis worldwide: it remains the most active service internationally with more than 150 patients (possible index cases and relatives of known cases) tested per year. Professor Hopkins has worked in the unit since 1988 and been its director since Further details of the service are attached. Since its foundation the Leeds MH Unit has combined research with its clinical service and this research has had a molecular genetic focus since Over the past 10 years research in the MH Unit has been funded by the Department of Health Pharmacogenetics programme, The Big Lottery Fund, the MRC and Wellcome Trust. Since 2012 the Leeds MH Unit has been a Core Component (PI Hopkins) of a US NIH Program Project Grant. See service description 16. Based on experience what will be the national (UK wide) activity, per annum, for: 16a. Index cases 75 16b. Family members where mutation is 100 known 17a. Does the laboratory have capacity to provide the expected national activity? Yes use of NGS for mutation detection will make the service already provided more efficient in terms of staff resources. 17b. If your laboratory does not have capacity to provide the full national need please could you provide information on how the national requirement may be met. For example, are you aware of any other labs (UKGTN members or otherwise) offering this test to NHS patients on a local area basis only? This question has been included in order to gauge if there could be any issues in equity of access for NHS patients. It is appreciated that some laboratories may not be able to answer this question. If this is the case please write unknown. 18. Please justify the requirement for another laboratory to provide this test e.g. insufficient national capacity. N/A
5 EPIDEMIOLOGY 19a. Estimated prevalence of condition in the general UK population 19b. Estimated incidence of condition in the general UK population Please identify the information on which this is based 20. Estimated gene frequency (Carrier frequency or allele frequency) Please identify the information on which this is based 21. Estimated penetrance Please identify the information on which this is based 22. Estimated prevalence of condition in the population of people that meet the Testing Criteria. Based on the incidence of MH in children (the age group with highest incidence), the likelihood of a child with MH susceptibility reacting during general anaesthesia and the number of children receiving general anaesthesia per year, we estimated the prevalence in the UK to be 1 in 8,000 10,000. The number of new cases of malignant hyperthermia presenting with a clinical reaction has averaged approximately 25 per year over the last 10 years. This represents an incidence of 1 in 2.4 million in the general population. However, only approximately 3 million people receive a general anaesthetic each year and so the incidence in the anaesthetic population is 1 in 120,000. The age distribution of those developing a reaction is skewed towards children and young adults, with an incidence of MH in children having general anaesthesia of 1 in 20,000 50,000. These data are based on referral patterns to the Leeds MH Unit (national referral centre) and are similar to epidemiological data from other countries. Using genetic data, Monnier and colleagues (ref) in France estimated the gene frequency at 1 in 3,000. Using similar methodology, we calculated a similar gene frequency for the UK. By definition MH can only occur in a patient receiving general anaesthesia and then only if the triggering drugs are used. Many patients react on their first anaesthetic exposure but some have had multiple general anaesthetics without apparent problems before subsequently reacting. The MH susceptibility phenotype, as defined by the in vitro contracture tests, is completely penetrant. For index cases who have been phenotyped MH susceptible using the in vitro contracture test, the prevalence is 100%. For index cases not tested initially by muscle biopsy, the prevalence will depend on which of the testing criteria they fulfilled. For example, in patients who developed a well documented fulminant metabolic reaction with rhabdomyolysis the prevalence is >95%. For those who present with a history of unexplained postoperative pyrexia the prevalence is approximately 1%. The overall prevalence for patients meeting any of the testing criteria is 30%.
6 INTENDED USE 23. Please tick either yes or no for each clinical purpose listed. Panel Tests: a panel test would not be used for pre symptomatic testing, carrier testing and pre natal testing as the familial mutation would already be known in this case and the full panel would not be required. Diagnosis x Yes No Treatment x Yes No Prognosis & management x Yes No Presymptomatic testing (n/a for panel tests) Yes No Carrier testing for family members (n/a for panel tests) Yes No Prenatal testing (n/a for panel tests) Yes No
7 TEST CHARACTERISTICS 24. Analytical sensitivity and specificity This should be based on your own laboratory data for the specific test being applied for or the analytical sensitivity and specificity of the method/technique to be used in the case of a test yet to be set up. Data 1) Total number of known variants by Gold standard (Sanger sequencing) re-tested by clonal sequencing: 485 Total number confirmed by clonal sequencing: 485 2) Number of unique variants (i.e. each variant counted once only) by Gold standard (Sanger sequencing) re-tested by clonal sequencing: 78 Total number confirmed by clonal sequencing: 78 Analysis Determined by binomial confidence interval method (see Using 95% confidence interval (2.5% in each tail). 1) Total number of variants (n=485) As no variants have been missed, binomial distribution predicts we can be 95% confident that the false negative rate is below 0.76%. However, it may be unrealistic to assume all variants are equally detectable, so considering each variant once only is a more cautious approach. 2. Number of unique variants The most cautious approach to validating clonal sequencing sensitivity would be to test a different variant each time, since re-testing a variant which is already know to be detectable is of limited value. Therefore, a repeat analysis was carried out counting only the total number of unique variants (n=78). Again, as no variants have been missed, binomial distribution predicts we can be 95% confident that the false negative rate is below 4.62%. Standard assumptions apply including: Quality standards for validation work are the same for subsequent patient tests. Testing criteria and methods remain unchanged or modifications do not have an impact on sensitivity. Samples tested (or the range of variants tested in validation) are representative of patients (or variants) that will be tested. Specificity of Illumina sequencing Common artefacts have been observed on numerous occasions at single nucleotide runs (As and Ts). Where these are detected at a significant level Sanger sequencing is used to exclude the presence of a variants. 25. Clinical sensitivity and specificity of test in target population The clinical sensitivity of a test is the probability of a positive test result when condition is known to be present; the clinical specificity is the probability of a negative test result when disorder is known to be absent. The denominator in this case is the number with the disorder (for sensitivity) or the number without condition (for specificity). For characterised diagnostic mutations ( Sensitivity: 40% Specificity: 95%
8 26. Clinical validity (positive and negative predictive value in the target population) The clinical validity of a genetic test is a measure of how well the test predicts the presence or absence of the phenotype, clinical condition or predisposition. It is measured by its positive predictive value (the probability of getting the condition given a positive test) and negative predictive value (the probability of not getting the condition given a negative test). For those with previous phenotyping using the in vitro contracture test: PPV, for those with MH susceptible phenotype= 100% NPV, for those with MH negative phenotype = 100% For those meeting the Test criteria with DNA analysis as the initial test PPV = 77% NPV = 79% 27. Testing pathway for tests where more than one gene is to be tested Please include your testing strategy if more than one gene will be tested and data on the expected proportions of positive results for each part of the process. Please illustrate this with a flow diagram. This will be added to the published Testing Criteria. Deep resequencing of RYR1 and CACNA1S will be done simultaneously. CLINICAL UTILITY 28. How will the test change the management of the patient and/or alter clinical outcome? A positive test will avoid the need for an open muscle biopsy, which involves a 2 night stay in Leeds. The biopsy is an open surgical procedure that leaves a scar of 5 8 cm and discomfort for up to two weeks. The average period of absence from work for the biopsy is 7 days. 29. Benefits of the test for the patient & other family members Please provide a summary of the overall benefits of this test. The test provides diagnosis without the need for open muscle biopsy. Diagnosis is important because it enables the appropriate choice of anaesthetic drugs for safe anaesthesia while minimising side-effects and complications. 30. What will be the consequences for patients and family members if this test is not approved? The only means of diagnosis will be the muscle biopsy procedure in Leeds 31. Is there an alternative means of diagnosis or prediction that does not involve molecular diagnosis? If so (and in particular if there is a biochemical test), please state the added advantage of the molecular test. See above 32. Please describe any specific ethical, legal or social issues with this particular test. MH susceptibility is generally a bar to recruitment to the military. There has always been a concern about the provision of safe anaesthesia for MH susceptible recruits on deployment. The more recent evidence that MH susceptible individuals are at increased risk of exertional rhabdomyolysis and possibly exertional heat illness has consolidated the situation. Serving members of the armed services who are newly diagnosed with MH susceptibility are handled on an individual basis in respect of their military careers. There may be other careers involving exposure to heat stress where risk to MH susceptible individuals is greater than normal.
9 33. Only complete this question if there is previously approved Testing Criteria and you do not agree with it. Please provide revised Testing Criteria on the Testing Criteria form and explain here the changes and the reasons for the changes. 34. List the diagnostic tests/procedures that an index case no longer needs if this genetic test is available. Type of test Cost ( ) Costs and type of imaging procedures Costs and types of laboratory pathology tests (other than molecular/cyto genetic test proposed in this gene dossier) Costs and types of physiological tests (e.g. ECG) Cost and types of other investigations/procedures (e.g. biopsy) Open muscle 3,500 biopsy with in vitro muscle contracture tests on the excised specimens and histopathological examination Total cost tests/procedures no longer required 3,500 (saving for people who are positive from genetic test) 35. Based on the expected annual activity of index cases (Q15a), please calculate the estimated annual savings/investments based on information provided in Q33. Number of index cases expected annually 75 Cost to provide tests for index cases if the genetic test in this gene dossier was not available (see Q34) 3,500 Total annual costs pre genetic test 262,500 Total annual costs to provide genetic test 39,750 Total savings 45 will still require the other tests 45x 3500 = 157,500 Total costs = 197, = 65,250 saving 36. REAL LIFE CASE STUDY In collaboration with the clinical lead, describe TWO real case examples: 1. prior to availability of genetic test 2. post availability of genetic test to illustrate how the test improves patient experience and the costs involved. Case example one pre genetic test Patient x was 4 years of age when he sustained a supracondylar fracture of his arm requiring urgent manipulation under general anaesthesia. As part of the anaesthetic procedure he was given suxamethonium which resulted in difficulty in opening x s mouth rather than causing the expected muscle relaxation. The jaw muscle relaxed after about two minutes and the operation continued with anaesthesia maintained using isoflurane. Towards the end of the 20 minute operation the anaesthetist became concerned that x s heart rate and end-tidal CO2 levels were increasing. However, as the surgery soon finished, isoflurane was discontinued and was woken up. The heart rate settled and other observations in the recovery period were normal other than a temperature of 37.8 C.
10 As x was too young to undergo the muscle biopsy procedure, both parents were referred for MH testing. The father tested negative and the mother positive. PRE GENETIC TEST COSTS Costs and type of imaging procedures Costs and type of laboratory pathology tests Costs and type of physiological tests (e.g. ECG) Cost and type of other investigations/procedures (e.g. biopsy) Type of test 2 x Open muscle biopsy with in vitro muscle contracture tests on the excised specimens histopathological examination and Cost 7,000 Cost outpatient consultations (genetics and non genetics) Total cost pre genetic test 7,000 Case example two post genetic test Patient y was 5 yrs old when he required an appendicectomy because of acute appendicitis. During the operation he developed a progressive rise in heart rate, end-tidal CO2 and temperature. When his temperature was 39.1 C the Isoflurane was discontinued, dantrolene administered and the patient actively cooled. The procedure was completed using intravenous anaesthesia and y made an uneventful recovery. When the family was informed that y had suffered a serious complication of anaesthesia, y s grandmother volunteered the information that one of her cousin s children had suffered from malignant hyperthermia. Referral of the family to the MH Unit in Leeds revealed that the previous index case had been confirmed as MH susceptible by muscle biopsy 10 years previously and subsequent DNA analysis detected a heterozygous RYR1 variant c.487c>t, p.arg163cys which meets international consensus criteria for diagnostic use in MH susceptibility. Patient y was found to carry the same RYR1 variant. POST GENETIC TEST COSTS Costs and type of imaging procedures Costs and types laboratory pathology tests (other than molecular/cyto genetic proposed in this gene dossier) Cost of genetic test proposing in this gene dossier Type of test Testing for known familial mutation Cost Costs and type of physiological tests (e.g. ECG) Cost and type of other investigations/procedures (e.g. biopsy) Cost outpatient consultations (genetics and non genetics) Total cost post genetic test Estimated savings between two case examples described 6,830
11 UKGTN Testing Criteria Test name: Malignant Hyperthermia Susceptibility 1 and 5 Approved name and symbol of disorder/condition(s): Malignant Hyperthermia, susceptibility to, 1 (MHS1) Malignant Hyperthermia, susceptibility to, 5 (MHS5) Approved name and symbol of gene(s): ryanodine receptor 1 (skeletal); RYR1 calcium channel, voltage-dependent, L type, alpha 1S subunit; CACNA1S OMIM number(s): OMIM number(s): Patient name: Patient postcode: Date of birth: NHS number: Name of referrer: Title/Position: Referrals will only be accepted from one of the following: Referrer Consultant Anaesthetist Consultant Clinical Geneticist Medical Officer, Institute of Naval Medicine (Military personnel) Lab ID: Tick if this refers to you. Minimum criteria required for testing to be appropriate as stated in the Gene Dossier: Criteria Tick if this patient Any one of the following: meets criteria Adverse reaction to general anaesthesia involving any combination of unexplained*: increase in carbon dioxide production, tachycardia, temperature increase, muscle rigidity, rhabdomyolysis, disseminated intravascular coagulation, death. Initial signs should be evident during anaesthesia or within 60 minutes of discontinuation of anaesthesia. Postoperative rhabdomyolysis and clinical exclusion of other myopathies Known case of malignant hyperthermia where no familial mutation identified Family history of malignant hyperthermia that has not been confirmed by muscle biopsy and/or where no familial mutation identified. Family history of unexplained perioperative death Exertional rhabdomyolysis or recurrent rhabdomyolysis where no cause identified following neurological work-up. Persistently raised serum creatine kinase concentration of unknown cause (idiopathic hyperckaemia). Other causes of raised creatine kinase should be excluded by neurologist.
12 Exertional heat stroke, especially in low-risk climatic conditions, where known predisposing factors have been excluded At risk family members where familial mutation is known. Additional Information: *The MH Unit in Leeds provides expert advice on the clinical features of malignant hyperthermia, none of which is specific for the condition. Of referrals of possible MH reactions made to the Unit, approximately 50% can be attributed to other causes and MH excluded on the basis of expert review of the clinical records. The MH Unit also maintains a national registry of MH cases and families and can advise on risk of family members and extent and findings of RYR1 and CACNA1S analyses in the family. For panel tests: At risk family members where familial mutation is known do not require a full panel test but should be offered analysis of the known mutation If the sample does not fulfil the clinical criteria or you are not one of the specified types of referrer and you still feel that testing should be performed please contact the laboratory to discuss testing of the sample.
Central core disease
Central core disease Central core disease falls under the umbrella of congenital myopathies which are characterised by muscle weakness and wasting. It is a rare condition, and symptoms are usually present
More informationGenetic diagnostics the gateway to personalized medicine
Micronova 20.11.2012 Genetic diagnostics the gateway to personalized medicine Kristiina Assoc. professor, Director of Genetic Department HUSLAB, Helsinki University Central Hospital The Human Genome Packed
More informationMinicore (multicore) myopathy
Minicore (multicore) myopathy Minicore myopathy, also called, multicore myopathy and multiminicore myopathy, falls under the umbrella of congenital myopathies. These are a group of conditions characterised
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationDiagnostic Scoring System for LQTS
Medical Coverage Policy Genetic Testing: Congenital Long QT Syndrome Device/Equipment Drug Medical Surgery Test Other Effective Date: 2/15/2011 Policy Last Updated: 2/21/2012 Prospective review is recommended/required.
More informationEuropean registered Clinical Laboratory Geneticist (ErCLG) Core curriculum
(February 2015; updated from paper issued by the European Society of Human Genetics Ad hoc committee for the accreditation of clinical laboratory geneticists, published in February 2012) Speciality Profile
More informationData Analysis for Ion Torrent Sequencing
IFU022 v140202 Research Use Only Instructions For Use Part III Data Analysis for Ion Torrent Sequencing MANUFACTURER: Multiplicom N.V. Galileilaan 18 2845 Niel Belgium Revision date: August 21, 2014 Page
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationAdvances in RainDance Sequence Enrichment Technology and Applications in Cancer Research. March 17, 2011 Rendez-Vous Séquençage
Advances in RainDance Sequence Enrichment Technology and Applications in Cancer Research March 17, 2011 Rendez-Vous Séquençage Presentation Overview Core Technology Review Sequence Enrichment Application
More informationTitle: Genetics and Hearing Loss: Clinical and Molecular Characteristics
Session # : 46 Day/Time: Friday, May 1, 2015, 1:00 4:00 pm Title: Genetics and Hearing Loss: Clinical and Molecular Characteristics Presenter: Kathleen S. Arnos, PhD, Gallaudet University This presentation
More informationDIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES
DIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES Extracts from a review article by KN North and KJ Jones: Recent advances in diagnosis of the childhood muscular dystrophies Journal of Paediatrics and Child Health
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for
More informationOverview of Genetic Testing and Screening
Integrating Genetics into Your Practice Webinar Series Overview of Genetic Testing and Screening Genetic testing is an important tool in the screening and diagnosis of many conditions. New technology is
More informationLecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs)
Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs) Single nucleotide polymorphisms or SNPs (pronounced "snips") are DNA sequence variations that occur
More informationBreast cancer and the role of low penetrance alleles: a focus on ATM gene
Modena 18-19 novembre 2010 Breast cancer and the role of low penetrance alleles: a focus on ATM gene Dr. Laura La Paglia Breast Cancer genetic Other BC susceptibility genes TP53 PTEN STK11 CHEK2 BRCA1
More informationNazneen Aziz, PhD. Director, Molecular Medicine Transformation Program Office
2013 Laboratory Accreditation Program Audioconferences and Webinars Implementing Next Generation Sequencing (NGS) as a Clinical Tool in the Laboratory Nazneen Aziz, PhD Director, Molecular Medicine Transformation
More informationHuman Genome Organization: An Update. Genome Organization: An Update
Human Genome Organization: An Update Genome Organization: An Update Highlights of Human Genome Project Timetable Proposed in 1990 as 3 billion dollar joint venture between DOE and NIH with 15 year completion
More informationInformation leaflet. Centrum voor Medische Genetica. Version 1/20150504 Design by Ben Caljon, UZ Brussel. Universitair Ziekenhuis Brussel
Information on genome-wide genetic testing Array Comparative Genomic Hybridization (array CGH) Single Nucleotide Polymorphism array (SNP array) Massive Parallel Sequencing (MPS) Version 120150504 Design
More informationEssential Nursing Competencies and Curricula Guidelines for Genetics and Genomics: Outcome Indicators
Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics: Outcome Indicators Introduction The Outcome Indicators are an adjunct to the Essential Nursing Competencies and Curricula
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS
More informationPatient Information. for Childhood
Patient Information Genetic Testing for Childhood Hearing Loss Introduction This document describes the most common genetic cause of childhood hearing loss and explains the role of genetic testing. Childhood
More informationWhat Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives
What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives What does the career involve? Explore family histories to identify risks Reducing risks
More informationAutomated DNA sequencing 20/12/2009. Next Generation Sequencing
DNA sequencing the beginnings Ghent University (Fiers et al) pioneers sequencing first complete gene (1972) first complete genome (1976) Next Generation Sequencing Fred Sanger develops dideoxy sequencing
More informationEuropean Medicines Agency
European Medicines Agency July 1996 CPMP/ICH/139/95 ICH Topic Q 5 B Quality of Biotechnological Products: Analysis of the Expression Construct in Cell Lines Used for Production of r-dna Derived Protein
More informationInsurance. Chapter 7. Introduction
65 Chapter 7 Insurance Introduction 7.1 The subject of genetic screening in relation to insurance is not new. In 1935 R A Fisher addressed the International Congress of Life Assurance Medicine on the topic,
More informationINTRODUCTION TO THE UK CURRICULUM IN CLINICAL GENETICS
INTRODUCTION TO THE UK CURRICULUM IN CLINICAL GENETICS Clinical Geneticists work in multidisciplinary regional genetic centres in the UK, in close collaboration with laboratory scientists, clinical co-workers
More informationUsher Syndrome Genetics
Usher Syndrome Genetics October 2012 Page 1 of 20 Introduction Usher syndrome is a genetic or inherited condition that affects hearing, vision and balance The sight loss is caused by an eye condition known
More informationThe following chapter is called "Preimplantation Genetic Diagnosis (PGD)".
Slide 1 Welcome to chapter 9. The following chapter is called "Preimplantation Genetic Diagnosis (PGD)". The author is Dr. Maria Lalioti. Slide 2 The learning objectives of this chapter are: To learn the
More informationZika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationGenomes and SNPs in Malaria and Sickle Cell Anemia
Genomes and SNPs in Malaria and Sickle Cell Anemia Introduction to Genome Browsing with Ensembl Ensembl The vast amount of information in biological databases today demands a way of organising and accessing
More informationGenetics Lecture Notes 7.03 2005. Lectures 1 2
Genetics Lecture Notes 7.03 2005 Lectures 1 2 Lecture 1 We will begin this course with the question: What is a gene? This question will take us four lectures to answer because there are actually several
More informationCRITICAL ILLNESS CLAIM FORM
CRITICAL ILLNESS CLAIM FORM Critical Illness Claim Form - Instructions Policyholder (employer or plan administrator) Please complete the Policyholder s Statement and ensure that you answer each question
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationGenetic Mutations Cause Many Birth Defects:
Genetic Mutations Cause Many Birth Defects: What We Learned from the FORGE Canada Project Jan M. Friedman, MD, PhD University it of British Columbia Vancouver, Canada I have no conflicts of interest related
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. Service Commissioner Lead Provider Lead Period Date of Review E01/Sb NHS Genomic Laboratory Services 1. Population Needs 1.1
More informationSingle-Cell Whole Genome Sequencing on the C1 System: a Performance Evaluation
PN 100-9879 A1 TECHNICAL NOTE Single-Cell Whole Genome Sequencing on the C1 System: a Performance Evaluation Introduction Cancer is a dynamic evolutionary process of which intratumor genetic and phenotypic
More informationFocusing on results not data comprehensive data analysis for targeted next generation sequencing
Focusing on results not data comprehensive data analysis for targeted next generation sequencing Daniel Swan, Jolyon Holdstock, Angela Matchan, Richard Stark, John Shovelton, Duarte Mohla and Simon Hughes
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationBecker Muscular Dystrophy
Muscular Dystrophy A Case Study of Positional Cloning Described by Benjamin Duchenne (1868) X-linked recessive disease causing severe muscular degeneration. 100 % penetrance X d Y affected male Frequency
More informationSICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE
AP Biology Date SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE LEARNING OBJECTIVES Students will gain an appreciation of the physical effects of sickle cell anemia, its prevalence in the population,
More informationRoberto Ciccone, Orsetta Zuffardi Università di Pavia
Roberto Ciccone, Orsetta Zuffardi Università di Pavia XIII Corso di Formazione Malformazioni Congenite dalla Diagnosi Prenatale alla Terapia Postnatale unipv.eu Carrara, 24 ottobre 2014 Legend:Bluebars
More informationTargeted. sequencing solutions. Accurate, scalable, fast TARGETED
Targeted TARGETED Sequencing sequencing solutions Accurate, scalable, fast Sequencing for every lab, every budget, every application Ion Torrent semiconductor sequencing Ion Torrent technology has pioneered
More information14.3 Studying the Human Genome
14.3 Studying the Human Genome Lesson Objectives Summarize the methods of DNA analysis. State the goals of the Human Genome Project and explain what we have learned so far. Lesson Summary Manipulating
More informationPrevention GENEration. The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
הסיכוי שבסיכון PREVENTION GENERATION Prevention GENEration The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC) We thank Prof. Ephrat Levy-Lahad Director, Medical
More informationCaring for Vulnerable Babies: The reorganisation of neonatal services in England
Caring for Vulnerable Babies: The reorganisation of neonatal services in England LONDON: The Stationery Office 13.90 Ordered by the House of Commons to be printed on 17 December 2007 REPORT BY THE COMPTROLLER
More informationHow many of you have checked out the web site on protein-dna interactions?
How many of you have checked out the web site on protein-dna interactions? Example of an approximately 40,000 probe spotted oligo microarray with enlarged inset to show detail. Find and be ready to discuss
More informationREQUEST FOR IMAGe SYNDROME TESTING
REQUEST FOR IMAGe SYNDROME TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION* FIRST NAME MI LAST
More informationCystic Fibrosis Webquest Sarah Follenweider, The English High School 2009 Summer Research Internship Program
Cystic Fibrosis Webquest Sarah Follenweider, The English High School 2009 Summer Research Internship Program Introduction: Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and
More informationGenetic Testing: Scientific Background for Policymakers
Genetic Testing: Scientific Background for Policymakers Amanda K. Sarata Specialist in Health Policy December 19, 2011 CRS Report for Congress Prepared for Members and Committees of Congress Congressional
More informationMRC-Holland MLPA. Description version 12; 02-12-2012
SALSA MLPA probemix P083-C1 CDH1 Lot C1-0211. As compared to previous B1 version, new in version C1: two CDH1 probes and several reference probes have been replaced/added. In addition, the 88 and 96nt
More informationPreimplantation Genetic Diagnosis (PGD) and Childhood Diagnostic Evaluation
IG O Preimplantation Genetic Diagnosis (PGD) and Childhood Diagnostic Evaluation KD Carsten Bergmann carsten.bergmann@bioscientia.de carsten.bergmann@uniklinik-freiburg.de Controversies Conference on ADPKD
More informationWhat should I expect before the procedure?
The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E- mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk PROCEDURE-
More informationRigid spine syndrome (RSS) (Congenital muscular dystrophy with rigidity of the spine, including RSMD1)
Rigid spine syndrome (RSS) (Congenital muscular dystrophy with rigidity of the spine, including RSMD1) What is RSMD1? The congenital muscular dystrophies are a group of conditions which share early presentation
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
More information2. True or False? The sequence of nucleotides in the human genome is 90.9% identical from one person to the next. False (it s 99.
1. True or False? A typical chromosome can contain several hundred to several thousand genes, arranged in linear order along the DNA molecule present in the chromosome. True 2. True or False? The sequence
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationThe National Institute of Genomic Medicine (INMEGEN) was
Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationHeart transplantation
Heart transplantation A patient s guide 1 Heart transplantation Heart transplantation has the potential to significantly improve the length and quality of life for patients with severe heart failure.
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationHeritability: Twin Studies. Twin studies are often used to assess genetic effects on variation in a trait
TWINS AND GENETICS TWINS Heritability: Twin Studies Twin studies are often used to assess genetic effects on variation in a trait Comparing MZ/DZ twins can give evidence for genetic and/or environmental
More informationThe timing of vaccination with respect to anaesthesia and surgery. 1. Surgery following immunisation with inactivated vaccines
The timing of vaccination with respect to anaesthesia and surgery Main recommendations: 1. Surgery following immunisation with inactivated vaccines Delay surgery 48 hours post vaccination to avoid postvaccination
More informationRevision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010
Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices Response from Cancer Research UK to the Commission August 2010 1. Cancer Research UK (CR-UK) 1 is leading the world in finding
More informationG. Shashidhar Pai, MD MUSC Children s Hospital Department of Pediatrics Division of Genetics
G. Shashidhar Pai, MD MUSC Children s Hospital Department of Pediatrics Division of Genetics One of every 500 newborns has bilateral permanent sensorineural hearing loss 40 db which makes it the most common
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationNext Generation Sequencing. mapping mutations in congenital heart disease
Next Generation Sequencing mapping mutations in congenital heart disease AV Postma PhD Academic Medical Center Amsterdam, the Netherlands Overview talk Congenital heart disease and genetics Next generation
More informationGenetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
More informationBio 102 Practice Problems Genetic Code and Mutation
Bio 102 Practice Problems Genetic Code and Mutation Multiple choice: Unless otherwise directed, circle the one best answer: 1. Beadle and Tatum mutagenized Neurospora to find strains that required arginine
More informationBoard of Member States ERN implementation strategies
Board of Member States ERN implementation strategies January 2016 As a result of discussions at the Board of Member States (BoMS) meeting in Lisbon on 7 October 2015, the BoMS set up a Strategy Working
More informationGene and Chromosome Mutation Worksheet (reference pgs. 239-240 in Modern Biology textbook)
Name Date Per Look at the diagrams, then answer the questions. Gene Mutations affect a single gene by changing its base sequence, resulting in an incorrect, or nonfunctional, protein being made. (a) A
More informationDelivering the power of the world s most successful genomics platform
Delivering the power of the world s most successful genomics platform NextCODE Health is bringing the full power of the world s largest and most successful genomics platform to everyday clinical care NextCODE
More informationBRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls?
BRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls? Giovanni Luca Scaglione, PhD ------------------------ Laboratory of Clinical Molecular Diagnostics and Personalized Medicine, Institute
More informationPrimePCR Assay Validation Report
Gene Information Gene Name sorbin and SH3 domain containing 2 Gene Symbol Organism Gene Summary Gene Aliases RefSeq Accession No. UniGene ID Ensembl Gene ID SORBS2 Human Arg and c-abl represent the mammalian
More informationFact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus Assay. June 17, 2016
Dear Health Care Provider: Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus Assay June 17, 2016 The U.S. Food and Drug Administration (FDA) has issued an Emergency
More informationCase-control studies. Alfredo Morabia
Case-control studies Alfredo Morabia Division d épidémiologie Clinique, Département de médecine communautaire, HUG Alfredo.Morabia@hcuge.ch www.epidemiologie.ch Outline Case-control study Relation to cohort
More informationUnderstanding Hereditary Breast and Ovarian Cancer. Maritime Hereditary Cancer Service
Understanding Hereditary Breast and Ovarian Cancer Maritime Hereditary Cancer Service General Information Cancer is very common. About one in three (33%) people are diagnosed with some form of cancer during
More informationPreimplantation Genetic Diagnosis (PGD) in Western Australia
Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome
More information1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease
The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2016 3/2017 3/2016 Description
More informationGENETIC TESTING AND MARFAN SYNDROME
GENETIC TESTING AND MARFAN SYNDROME Genetic testing for mutations in fibrillin-1 (FBN1) and other genes has become an important and reliable option to aid in the diagnosis of Marfan syndrome and related
More informationTrauma Insurance Claims Seminar Invitation
Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims
More informationPatient Information. Ordering Physician Information. Indication for Testing (REQUIRED)
EPILEPSY EXOME CLINICAL CHECKLIST REQUIRED Please check all clinical features that apply, and use the additional space provided at the bottom of the form if needed Patient Information Name: Last First
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationWhy Disruptive Innovations Matter in Laboratory Diagnostics
Article: S. Nam.. Clin Chem 2015;61:935-937. http://www.clinchem.org/content/61/7/935.extract Guest: Spencer Nam is a Research Fellow specializing in healthcare at the Clayton Christensen Institute for
More informationBRCA in Men. Mary B. Daly,M.D.,Ph.D. June 25, 2010
BRCA in Men Mary B. Daly,M.D.,Ph.D. June 25, 2010 BRCA in Men Inheritance patterns of BRCA1/2 Cancer Risks for men with BRCA1/2 mutations Risk management recommendations for men with BRCA1/2 mutations
More informationMRC-Holland MLPA. Related SALSA MLPA probemix P091 CFTR: contains probes for the CFTR gene, related to chronic pancreatitis.
SALSA MLPA probemix P242-B3 Pancreatitis Lot B3-0215. As compared to version B2 (lot B2-1212), one flanking probe has been removed and four reference probes have been replaced. Hereditary Pancreatitis
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationThis fact sheet describes how genes affect our health when they follow a well understood pattern of genetic inheritance known as autosomal recessive.
11111 This fact sheet describes how genes affect our health when they follow a well understood pattern of genetic inheritance known as autosomal recessive. In summary Genes contain the instructions for
More informationIMMEDIATE HOT LINE: Effective March 2, 2015
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationCAGC Certification Logbook of Clinical Experience INSTRUCTIONS
CAGC Certification Logbook of Clinical Experience INSTRUCTIONS The purpose of the logbook is to show that the applicant has been significantly involved in the evaluation and counselling of patients seeking
More informationMendelian inheritance and the
Mendelian inheritance and the most common genetic diseases Cornelia Schubert, MD, University of Goettingen, Dept. Human Genetics EUPRIM-Net course Genetics, Immunology and Breeding Mangement German Primate
More informationGenomic Medicine Education Initiatives of the College of American Pathologists
Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical
More informationGenetic Testing for Duchenne and Becker Muscular Dystrophy
Corporate Medical Policy Genetic Testing for Duchenne and Becker Muscular Dystrophy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_duchenne_and_becker_muscular_dystrophy
More informationMUSCLE BIOPSY FREQUENTLY ASKED QUESTIONS. for mitochondrial and metabolic disorders
MUSCLE BIOPSY for mitochondrial and metabolic disorders FREQUENTLY ASKED QUESTIONS Note: The information contained in this document is not intended nor should it replace a one on one discussion about your
More informationThe RCGP Curriculum: Clinical Modules
The RCGP Curriculum: Clinical Modules Version approved 18 May 2015 for implementation from 5 August 2015 3.02 Genetics in Primary Care Summary It has been estimated that at least one in ten of the patients
More informationSingle-Cell DNA Sequencing with the C 1. Single-Cell Auto Prep System. Reveal hidden populations and genetic diversity within complex samples
DATA Sheet Single-Cell DNA Sequencing with the C 1 Single-Cell Auto Prep System Reveal hidden populations and genetic diversity within complex samples Single-cell sensitivity Discover and detect SNPs,
More informationCorporate Medical Policy Genetic Testing for Hereditary Hearing Loss
Corporate Medical Policy Genetic Testing for Hereditary Hearing Loss File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_hereditary_hearing_loss 10/2013 8/2015 8/2016
More informationUmm AL Qura University MUTATIONS. Dr Neda M Bogari
Umm AL Qura University MUTATIONS Dr Neda M Bogari CONTACTS www.bogari.net http://web.me.com/bogari/bogari.net/ From DNA to Mutations MUTATION Definition: Permanent change in nucleotide sequence. It can
More information